U.S. Markets closed

Apyx Medical Corporation (APYX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.21-0.05 (-0.54%)
At close: 4:00PM EDT
9.21 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.26
Open9.13
Bid8.28 x 1100
Ask10.95 x 1100
Day's Range9.07 - 9.30
52 Week Range4.35 - 12.01
Volume21,771
Avg. Volume84,500
Market Cap316.068M
Beta (5Y Monthly)0.75
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2021 Financial Results on August 12, 2021
    Business Wire

    Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2021 Financial Results on August 12, 2021

    CLEARWATER, Fla., July 12, 2021--Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the second quarter of fiscal year 2021 will be released before the market opens on Thursday, August 12th.

  • Business Wire

    Apyx Medical Corporation to Participate in the JMP Securities Life Sciences Conference

    Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that management will participate in the JMP Securities Life Sciences Conference, which is being held virtually from June 16th-17th. Management will participate in a fireside chat on Wednesday, June 16th at 10:30 a.m. Eastern Time.

  • Business Wire

    Apyx Medical Corporation Announces FDA 510(k) Submission for the Use of Renuvion® in Dermal Resurfacing Procedures

    Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration ("FDA"), which is intended to obtain a specific clinical indication for the use of Renuvion in dermal resurfacing procedures.